Lv1
100 积分 2024-04-28 加入
Chronic Myeloid Leukemia A Review
1个月前
已完结
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria
1个月前
已完结
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
1个月前
已完结
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
1个月前
已完结
Clinical features and survival of asian pediatric patients with paroxysmal nocturnal hemoglobinuria: results from a single center in China
1个月前
已完结
Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis
1个月前
已完结
Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria
1个月前
已完结
Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma
1个月前
已关闭
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study
1个月前
已完结
HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance
1个月前
已完结
皖公网安备34019202002308
